EP1085863A4 - NEW MEDICINES FOR THE TREATMENT OF FAULTS CAUSED BY CALCIUM CHANNELS AND THEIR USE - Google Patents

NEW MEDICINES FOR THE TREATMENT OF FAULTS CAUSED BY CALCIUM CHANNELS AND THEIR USE

Info

Publication number
EP1085863A4
EP1085863A4 EP99928427A EP99928427A EP1085863A4 EP 1085863 A4 EP1085863 A4 EP 1085863A4 EP 99928427 A EP99928427 A EP 99928427A EP 99928427 A EP99928427 A EP 99928427A EP 1085863 A4 EP1085863 A4 EP 1085863A4
Authority
EP
European Patent Office
Prior art keywords
cross
related applications
applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99928427A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1085863A1 (en
Inventor
Yu-Hau Ji
Maya Natarajan
John H Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of EP1085863A1 publication Critical patent/EP1085863A1/en
Publication of EP1085863A4 publication Critical patent/EP1085863A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
EP99928427A 1998-06-08 1999-06-07 NEW MEDICINES FOR THE TREATMENT OF FAULTS CAUSED BY CALCIUM CHANNELS AND THEIR USE Withdrawn EP1085863A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US88465P 1998-06-08
US9306898P 1998-07-16 1998-07-16
US93068P 1998-07-16
US10386698P 1998-10-12 1998-10-12
US103866P 1998-10-12
PCT/US1999/012672 WO1999063992A1 (en) 1998-06-08 1999-06-07 Novel calcium channel drugs and uses

Publications (2)

Publication Number Publication Date
EP1085863A1 EP1085863A1 (en) 2001-03-28
EP1085863A4 true EP1085863A4 (en) 2001-03-28

Family

ID=27375969

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99928427A Withdrawn EP1085863A4 (en) 1998-06-08 1999-06-07 NEW MEDICINES FOR THE TREATMENT OF FAULTS CAUSED BY CALCIUM CHANNELS AND THEIR USE

Country Status (7)

Country Link
EP (1) EP1085863A4 (ja)
JP (1) JP2002517440A (ja)
AR (1) AR020876A1 (ja)
AU (1) AU4549399A (ja)
CA (1) CA2318901A1 (ja)
SG (1) SG80038A1 (ja)
WO (1) WO1999063992A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101909B2 (en) 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
DK1628663T3 (da) 2003-05-15 2010-03-08 Roskamp Res Llc Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose
CA2701620C (en) 2007-10-05 2014-12-09 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052300A1 (de) * 1980-11-13 1982-05-26 Bayer Ag C-3 verknüpfte 1,4-Dihydropyridine, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung
US4532248A (en) * 1981-07-30 1985-07-30 Bayer Aktiengesellschaft Method of combatting coronary and vascular diseases
WO1996033972A1 (en) * 1995-04-28 1996-10-31 Glaxo Group Limited Methods for synthesizing diverse collections of pyridines, pyrimidines, 1,4-dihydro derivatives thereof, and piperidine derivatives
US5723618A (en) * 1995-11-01 1998-03-03 Apotex, Inc. 1,4-dihydropyridines, N-substituted bicyclic 4-hydropyridines, and bicyclic N-substituted 4,5-dihydropyridines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6403305B1 (en) * 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052300A1 (de) * 1980-11-13 1982-05-26 Bayer Ag C-3 verknüpfte 1,4-Dihydropyridine, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung
US4532248A (en) * 1981-07-30 1985-07-30 Bayer Aktiengesellschaft Method of combatting coronary and vascular diseases
WO1996033972A1 (en) * 1995-04-28 1996-10-31 Glaxo Group Limited Methods for synthesizing diverse collections of pyridines, pyrimidines, 1,4-dihydro derivatives thereof, and piperidine derivatives
US5723618A (en) * 1995-11-01 1998-03-03 Apotex, Inc. 1,4-dihydropyridines, N-substituted bicyclic 4-hydropyridines, and bicyclic N-substituted 4,5-dihydropyridines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOSLYN, ALAN F. ET AL: "Dimeric 1,4-dihydropyridines as calcium channel antagonists", J. MED. CHEM. (1988), 31(8), 1489-92, XP002143667 *
See also references of WO9963992A1 *

Also Published As

Publication number Publication date
EP1085863A1 (en) 2001-03-28
CA2318901A1 (en) 1999-12-16
WO1999063992A9 (en) 2002-08-22
JP2002517440A (ja) 2002-06-18
AU4549399A (en) 1999-12-30
SG80038A1 (en) 2001-04-17
AR020876A1 (es) 2002-06-05
WO1999063992A8 (en) 2001-02-22
WO1999063992A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
DE69909613D1 (en) Bicyclische hydroxamsäurederivate
DE59912932D1 (en) Arylphenylsubstituierte cyclische ketoenole
DE59912303D1 (en) Arylphenylsubstituierte cyclische ketoenole
DE69913545D1 (en) Pyrimidonderivate
PL341642A1 (en) Novel macrolydes
DE69904335D1 (en) Aminomethylcarbonsäurederivate
DE69914921D1 (en) Phenyl-xanthinderivate
DE69835235D1 (en) Thermoplastische silikonelastomere
DE59903023D1 (en) Perorale wirkstoff-suspension
DE59914151D1 (en) Arylalkanoylpyridazine
DE69915628D1 (en) Ritonavir-polymorph
DE60042897D1 (en) Photovervielfacherröhre
EP1068213A4 (en) SILOXANES WITH AMINO-ORGANIC FUNCTIONAL GROUP
DE69904442D1 (en) Cyclohexandiol-derivate
AU136536S (en) Case
DE69925859D1 (en) Cycloalkylsubstituierte aminomethylpyrrolidin-derivate
DE59904407D1 (en) Chromanderivate
DE69821502D1 (en) Boroskop
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
HK1039937A1 (zh) 取代的3-硫代氨基甲酰基吡唑類化合物
DE59900495D1 (en) Multimetalloxidmassen
DE59900471D1 (en) Inchbremseinrichtung
EP1085863A4 (en) NEW MEDICINES FOR THE TREATMENT OF FAULTS CAUSED BY CALCIUM CHANNELS AND THEIR USE
DE69912430D1 (en) Hydroformylierungsreaktionen
HUP0102476A3 (en) Substituted cyclooctadepsipeptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000616

A4 Supplementary search report drawn up and despatched

Effective date: 20001128

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THERAVANCE, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020905